Literature DB >> 29509925

Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies.

Roberto Minutolo1, Francis B Gabbai2, Michele Provenzano1, Paolo Chiodini3, Silvio Borrelli1, Carlo Garofalo1, Ferdinando C Sasso4, Domenico Santoro5, Vincenzo Bellizzi6, Giuseppe Conte1, Luca De Nicola1.   

Abstract

Background: No study has assessed whether the prognosis of coexisting diabetes mellitus and chronic kidney disease (DM-CKD) is dictated by DM per se or by the extent of proteinuria.
Methods: In this pooled analysis of four prospective studies in CKD patients treated with drugs inhibiting the renin-angiotensin system, we compared the risk of all-cause mortality, fatal and non-fatal cardiovascular (CV) events and end-stage renal disease (ESRD) between patients with (n = 693) and without diabetes (n = 1481) stratified by proteinuria level (<0.15, 0.15-0.49, 0.5-1 and  >1 g/day).
Results: The group with DM-CKD was older (69 ± 11 versus 65 ± 15 years), had a higher body mass index (29.6 ± 5.4 versus 27.5 ± 4.8 kg/m2) and systolic blood pressure (143 ± 19 versus 136 ± 18 mmHg), prevalent CV disease (48% versus 29%) and lower estimated glomerular filtration rate (34.5 ± 17.9 versus 36.6 ± 19.0 mL/min/1.73 m2). During 4.07 years of follow-up, there were 466 patients with ESRD, 334 deaths and 401 CV events occurred. In the subgroup with urine protein <0.15 g/day (N = 662), the risks of ESRD, CV events and mortality were similar in diabetic and non-diabetic patients. Conversely, in DM-CKD patients, the mortality risk was higher in proteinuric patients {hazard ratio 1.92 [95% confidence interval (CI) 1.25-2.95); 1.99 (1.26-3.15) and 1.98 (1.28-3.06) for proteinuria 0.15-0.49, 0.5-1 and >1 g/day, respectively}, whereas in non-diabetics the mortality risk increased only for proteinuria 0.5-1 g/day [HR 1.60 (95% CI 1.07-2.40)] and >1 g/day [HR 1.69 (95% CI1.20-2.55)]. In both groups, CV risk had a trend similar to that of mortality. ESRD risk increased progressively across strata >0.5 g/day independent of diabetic status. Conclusions: We provide evidence that patients with non-proteinuric DM-CKD are not exposed to higher cardiorenal risk. In contrast, in the presence of moderate proteinuria and diabetes per se is associated with a higher risk of mortality and CV events, whereas the entity of abnormal proteinuria modulates ESRD risk independent of diabetes.

Entities:  

Mesh:

Year:  2018        PMID: 29509925     DOI: 10.1093/ndt/gfy032

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  37 in total

1.  Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics.

Authors:  Roberto Minutolo; Luca De Nicola; Ciro Gallo; Paolo Chiodini; Michele Provenzano; Giuseppe Conte; Carlo Garofalo; Silvio Borrelli
Journal:  J Nephrol       Date:  2019-01-23       Impact factor: 3.902

2.  Incidence of Diabetic Retinopathy and Its Predictors Among Newly Diagnosed Type 1 and Type 2 Diabetic Patients: A Retrospective Follow-up Study at Tertiary Health-care Setting of Ethiopia.

Authors:  Gebiso Roba Debele; Shuma Gosha Kanfe; Adisu Birhanu Weldesenbet; Galana Mamo Ayana; Wakuma Wakene Jifar; Temam Beshir Raru
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-22       Impact factor: 3.168

3.  Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers.

Authors:  Stefanos Roumeliotis; Vassilios Liakopoulos; Athanasios Roumeliotis; Aikaterini Stamou; Stylianos Panagoutsos; Graziella D'Arrigo; Giovanni Tripepi
Journal:  Clin Diabetes       Date:  2021-04

4.  Natural history and prognostic implications of left ventricular end-diastolic pressure in reperfused ST-segment elevation myocardial infarction: an analysis of the thrombolysis in myocardial infarction (TIMI) II randomized controlled trial.

Authors:  Arshad A Khan; Mohammed S Al-Omary; Nicholas J Collins; John Attia; Andrew J Boyle
Journal:  BMC Cardiovasc Disord       Date:  2021-05-17       Impact factor: 2.298

5.  Impact of Isolated High Home Systolic Blood Pressure and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A 5-Year Prospective Cohort Study.

Authors:  Nobuko Kitagawa; Noriyuki Kitagawa; Emi Ushigome; Hidetaka Ushigome; Isao Yokota; Naoko Nakanishi; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Michiaki Fukui
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

Review 6.  Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease.

Authors:  Swayam Prakash Srivastava; Julie E Goodwin; Pratima Tripathi; Keizo Kanasaki; Daisuke Koya
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

Review 7.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

8.  A Randomized Trial of Tai Chi on Preventing Hypertension and Hyperlipidemia in Middle-Aged and Elderly Patients.

Authors:  Jiansheng Wen; Min Su
Journal:  Int J Environ Res Public Health       Date:  2021-05-20       Impact factor: 3.390

Review 9.  Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.

Authors:  Michele Provenzano; Maria Chiara Pelle; Isabella Zaffina; Bruno Tassone; Roberta Pujia; Marco Ricchio; Raffaele Serra; Angela Sciacqua; Ashour Michael; Michele Andreucci; Franco Arturi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

10.  Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease.

Authors:  Ferdinando Carlo Sasso; Pia Clara Pafundi; Vittorio Simeon; Luca De Nicola; Paolo Chiodini; Raffaele Galiero; Luca Rinaldi; Riccardo Nevola; Teresa Salvatore; Celestino Sardu; Raffaele Marfella; Luigi Elio Adinolfi; Roberto Minutolo
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.